Studies

Sean Parker Partners With Cancer Research Institute for a Cancer Vaccine Development Using Bioinformatics

By on
Sean Parker's Institute Partners With Cancer Research Institute for a Cancer Vaccine Development Using Bioinformatics
PHOTOGRAPH: Jaytaix/Pixabay |

A collective effort may deliver us to a cancer vaccine development soon. The Parker Institute for Cancer Immunotherapy partners with various organizations to find a way in preventing one of the world’s leading causes of death.

The lifestyle of today’s generation has impacted the health of the people, and more so in the future. Having poor diet, less physical activity, and habits such as smoking only increase the risk of people in contracting cancer which has over a hundred types.

Unified Effort to Combat Cancer

According to the American Society of Cancer, 14.1 million new cancer cases were reported in 2012 which caused 8.2 million deaths worldwide. The number is only expected to grow by 2030 up to 21.7 million that would become a cause of 13 million cancer deaths.

That is why finding a treatment and preventing it is more critical now than ever. With that, tech billionaire Sean Parker, through his Parker Institute for Cancer Immunotherapy, is trying to find a way to halt this global health threat once and for all.

The cancer institute, a collaborative effort of six research universities and cancer centers, has already poured their efforts in various research before. This time, the bar is raised as over 30 organizations from both private and public academic institutions, biotech, cancer research nonprofits and pharmaceuticals joined in through the Cancer Research Institute.

This time, the Cancer Research Institute’s goal is to focus on bioinformatics that would unveil neoantigens, the markers carried by cancer tumors. If they are successful, more effective treatments and prevention measures would be developed.

Bioinformatics to Expose Cancer Markers

Parker envisions that algorithms can be used to detect neoantigens through the use of bioinformatics. Because they are only present on tumors, these neoantigens appear to be perfect targets for newer immunotherapy treatments. These are also called biologic therapies that are designed to boost the body’s natural defenses in order to combat cancer.

Ramy Ibrahim, Vice President of Parker Institute for Cancer Immunotherapy’s clinical development says the cancer tumor markers would be an important groundwork for “accelerating immunotherapy research.” Meanwhile, all participating groups would do the research to gather the data needed in the cancer vaccine development.Parker has already funded $250 million to his cancer research institute just to support the study of some of the best researchers in the country in hopefully solving cancer.

This is undoubtedly a daring collaboration initiative in the medical field. In fact, Parker has already funded $250 million to his cancer research institute just to support the study of some of the best researchers in the country in the hope of solving cancer.

Parker says the alliance of the organizations would “harness the power of bioinformatics.” He also shares bringing together “the world’s best neoantigen research organization” was what he initially envisioned in creating the Parker’s Institute for to eventually open avenues for cancer vaccine development and personalized immunotherapies.

Comments

About the author

To Top